Dr. A. Anusha, Dr. M. V. Reddy, Dr. P. Vijayendra


INTRODUCTION: Diabetic ulcer is a signicant healthcare problem with its healing depending on many factors. Many
agents have been tried in wound healing and one such agent is phenytoin. The aim of this prospective comparative study
was to compare the efcacy of topical phenytoin with conventional wound dressings in the healing of diabetic ulcers.
PATIENTS AND METHODS: This prospective comparative study included fty patients, with 25 patients in each group. The patients were
compared in terms of number of days required for healing, rate of granulation tissue formation, effect on bacterial load and skin graft up take.
OBSERVATIONS AND RESULTS: Both the groups were comparable in terms of patient demographics. Rate of granulation tissue formation
was more rapid in phenytoin group with a mean of 85.21% as compared to conventional moist dressing group with a mean of 70.32%. Hospital
stay was signicantly reduced in phenytoin group with a mean of 30.04 days compared to conventional moist dressing group with a mean of
45.10 days. Percentage of graft uptake is more in phenytoin group with a mean of 91.78% compared to conventional moist dressing group with a
mean of 75.48%.
CONCLUSION: Rate of granulation tissue formation, overall graft uptake, patient compliance and overall hospital stay were better in the
topical phenytoin dressing group. Thus, topical phenytoin moist wound dressing can be considered as a superior option in the management of
diabetic ulcers.


Diabetic ulcers, Topical phenytoin, Conventional moist dressings.

Full Text:



Calhoun, J., Overgaard, K., Stevens, C., Dowling, J. and Mader, J. (2002). Diabetic Foot Ulcers and Infections:Current Concepts. Advances in Skin & Wound Care, 15(1), pp.31-42.

Younes N, Albsoul A, Badran D, and Obedi. Wound bed preparation with 10 percent phenytoin ointment increases the take of split-thickness skin graft in large diabetic ulcers. Dermatol Online 2006; 12(6): 5.

Pendsey, S. Understanding diabetic foot. International Journal of Diabetic in developing countries. 2010; 30(2): 75.

Meritt HH, and Putnam TJ. Sodium diphenylhydantoinate in the treatment of convulsive disorders. JAMA. 1938;111:1068-1073

Silverman AK, Fairley J, and Wongs RC. Cutaneous and Immunologic reactions to phenytoin. J. Am. Acad. Dermatol. 1988;18:721-741.

Bethedsa MD. ASHP drug information. American Society of Health System Pharmacists. 2001; P2081.

Oluwatosin OM, Olabanji JK, Oluwatosin OA, Tijani LA, Onyechi HU. A comparison of topical honey and phenytoin in the treatment of chronic leg ulcers. Afr J Med Med Sci. 2000; 29:31-4.

Bhatia A, Prakash S. Topical phenytoin for wound healing. Dermatol Online J. 2004; 10(1):5.

Muthukumarasamy MG, Sivakumar G, ManoharanG.Topical phenytoin in diabetic foot ulcers. Diabetes Care. 1991; 14:909-11.

Margolis DJ, Lewis VL. A literature assessment of the use of miscellaneous topical agents, growth factors, and skin equivalents for the treatment of pressure ulcers. Dermatol Surg. 1995;21:145-8.

Leo FTauro, Prathvi Shetty, Nita T Dsouza, SaleemMohammed, Suresh Sucharitha. Phenytoin vs Conventional Wound Care in Diabetic Ulcers. International Journal of Molecular Medical Science. 2013; Vol. 3, No. 8.

Pai M, Sitaraman N, Kotian M S. Topical phenytoin in diabetic ulcers: A double blind controlled trial. Indian J Med Sci [serial online] 2001 [cited 2015 Oct 4];55:593-9.

Rituraj, Sunil Aggarwal. Topical Phenytoin: Role in Diabetic Ulcer Care. International Journal of Interdisciplinary and Multidisciplinary Studies (IJIMS), 2015; 2(6): 93-97.

Vijaya Patel,RashmiPatil. Topical Phenytoin Application in Grade I and II Diabetic Foot Ulcers: A Prospective Study. J ClinDiagn Res. 2013 Oct; 7(10): 2238–2240.


  • There are currently no refbacks.